Stocks

Marvell fell exactly 7.75% to 217.53 USD on July 13, 2026 as the semiconductor rout triggered broad AI-chip selling and pushed MRVL below its 50-day moving average. Read the daily analysis of Marvell’s AI outlook, downside momentum and key support levels.

Figma rose exactly 12.03% to 23.65 USD on July 13, 2026 as high short interest and renewed buying triggered a short squeeze. Read the daily analysis of Figma’s AI growth outlook, improving price structure and key breakout levels.

AppLovin fell exactly 12.65% to 442.85 USD on July 13, 2026 as concerns over its muted e-commerce rollout and the broader technology sell-off triggered heavy selling. Read the daily analysis of AppLovin’s growth outlook, valuation risks and key moving averages.

Apple rose exactly 0.63% to 317.31 USD on July 13, 2026 as shares reached a new all-time intraday high despite the broader technology sell-off. Read the daily analysis of Apple’s relative strength, record-high breakout and key technical levels.

SanDisk fell exactly 12.63% to 1,673.97 USD on July 13, 2026 as SK Hynix’s record decline spread across memory stocks and triggered profit-taking after SanDisk’s exceptional 2026 rally. Read the daily analysis of its memory outlook, valuation risks and key support levels.

Oracle fell exactly 6.47% to 131.54 USD on July 13, 2026 as its S&P credit downgrade intensified concerns over AI infrastructure spending, financing needs and negative free cash flow. Read the daily analysis of Oracle’s AI expansion, credit risks and key technical levels.

Micron fell exactly 4.32% to 937.00 USD on July 13, 2026 as a global memory-chip sell-off and future capacity concerns triggered profit-taking. Read the daily analysis of Micron’s HBM outlook, valuation risks and key 902.60–907.42 USD support zone.

HCLTech reported first-quarter profit and revenue that beat expectations, but kept its fiscal 2027 constant-currency revenue growth guidance at 1%-4% and its EBIT margin guidance at 17.5%-18.5%. Several brokerages said the unchanged outlook underscores ongoing softness in tech spending by clients in financial services, telecom and manufacturing, alongside pressure from advanced AI tools. While bookings improved, the market read the steady guidance as confirmation that demand remains fragile.

The US Food and Drug Administration issued a warning letter dated July 10, 2026, to a clinical investigator linked to a bioequivalence study conducted at Alembic Pharma’s Vadodara facility. The letter followed an inspection conducted between March 3 and March 7, 2025, and cited issues related to the Informed Consent Form used in the study. Alembic said the observations are not related to data integrity and that the warning letter does not restrict facility operations or have a material financial impact at this stage. The company said the matter could slow the review of its abbreviated new drug application (ANDA) submissions to the USFDA, raising investor concerns about export risks.

HCL Technologies reported FY26 Q1 results, with net profit up 20% year on year to Rs 4,624 crore and revenue rising 14% to Rs 34,579 crore, while operating margin improved to 16.9%. The company kept its FY27 revenue growth guidance of 1-4% and EBIT margin guidance of 17.5-18.5%, and announced a Rs 3,500 crore investment in an AI data centre. Broker views diverged, with Citi cutting the stock to Sell, Nomura maintaining Buy and raising its target to Rs 1,290, while CLSA, Goldman Sachs and HSBC stayed broadly cautious and neutral.